June 2021

Therapeutic Options for Patients With High-Risk, HER2-Positive Early Breast Cancer

Posted on June 24, 2021 by Womens Cancer Care

Therapeutic Options for Patients With High-Risk, HER2-Positive Early Breast Cancer The researchers found that adding 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival and that the risk: benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastuzumab. Efficacy was similar, and there were fewer acute toxic effects and lower risks of […]

MammaPrint 70-Gene Signature Identifies Ultralow-Risk Patients With Outstanding Prognosis in Breast Cancer

Posted on June 11, 2021 by Womens Cancer Care

Researchers evaluated the clinical utility of genetic testing with MammaPrint 70-gene signature to determine how well this assay works in comparison with clinical assessment to determine the need for chemotherapy in women with breast cancer involving 0 to 3 lymph nodes. The phase 3 MINDACT findings, which included the survival outcomes of patients with an […]